Lokavant Releases AI-Based Forecasting Tool for Clinical Trial Enrollment
Lokavant has launched Spectrum v15, an AI-powered clinical trial forecasting platform designed to reduce uncertainty in feasibility planning and enrollment timelines. Built on a historical dataset covering over 500,000 clinical trials, the system replaces manual comparator setup (traditionally requiring five weeks of effort) with automated modeling allegedly completed in as little as five minutes.
The platform integrates machine learning, generative AI, and causal inference models to forecast outcomes with over 80 percent confidence. It enables granular scenario planning across sites, countries, and regions, both before trial initiation and during execution. Spectrum also supports adaptive trial designs and continuous re-forecasting in response to protocol changes or participant attrition.
According to Pfizer’s Head of Predictive Analytics, Jonathan Crowther, Spectrum offers a shift from static planning to dynamic, data-responsive decision-making—essential for addressing growing trial complexity and volatility. The platform has already been adopted by multiple biotechnology sponsors for enrollment risk modeling and feasibility optimization.
Lokavant will present Spectrum at DIA 2025, where the company is emphasizing its application for real-time, multi-variable forecasting in both traditional and adaptive trial contexts.
